Perceptions, Current Practices and Interventions of Community Pharmacists Regarding Antimicrobial Stewardship: A Qualitative Study in France

Claire Durand (durand.c@chu-nice.fr)
Centre Hospitalier Universitaire de Nice  https://orcid.org/0000-0001-6109-2402

Aude Chappuis
URPS Pharmaciens Ile-de-France

Eric Douriez
URPS Pharmaciens Ile-de-France

Frédérique Poulain
URPS Pharmaciens Ile-de-France

Raheelah Ahmad
National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance

François-Xavier Lesure
INSERM U1137

Nathan Peiffer-Smadja
INSERM U1137

Research

Keywords: Antibiotic stewardship, community pharmacists, primary care, implementation research, Consolidated Framework for Implementation Research

Posted Date: November 9th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1033731/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background: Community health care accounts for the vast majority of antibiotic use in Europe. Given the threat of antimicrobial resistance (AMR), there is an urgent need to develop new antimicrobial stewardship (AMS) interventions in primary care that could involve different health care providers including community pharmacists. This study aimed to explore the perceptions, current practices and interventions of community pharmacists regarding antimicrobial stewardship.

Methods: Semi-structured qualitative interviews were conducted with community pharmacists in France. Participants were recruited through a professional organization of community pharmacists combined with a snowballing technique. Interviews were audio recorded, transcribed and analyzed using thematic analysis. The Consolidated Framework for Implementation Research was used while developing the interview guide and carrying out thematic analysis.

Results: Sixteen community pharmacists participated. All the respondents had good awareness about antimicrobial resistance and believed community pharmacists had an important role in tackling AMR. Some barriers to community pharmacists’ participation in AMS were identified such as difficult interactions with prescribers, lack of time and lack of access to patient medical records and diagnosis. Increased patient education, audits and feedback of antibiotic prescribing, increased point-of-care testing and delayed prescribing were interventions suggested by the pharmacists to improve antibiotic use in primary care. Strategies cited by participants to facilitate the implementation of such interventions are increased pharmacist-general practitioner collaboration, specialized training, clinical decision support tools as well as financial incentives.

Conclusions: This study suggests that community pharmacists could play a greater role in infection management and AMS interventions. Further interprofessional collaboration is needed to optimize antibiotic prescribing and utilization in community health care.

Contributions To The Literature

- Community pharmacists are well-positioned and well-regarded health care providers who could play a greater role in the management of common infections and antimicrobial stewardship in primary care.
- This article identifies several opportunities for antimicrobial stewardship interventions in community pharmacies despite some barriers, both internal and external to the pharmacy environment.
- Our findings highlight multiple facilitators that could support the successful implementation of antimicrobial stewardship activities into community pharmacy practice.

Introduction

Background

Antimicrobial resistance (AMR) is a major public health concern, listed by the World Health Organization (WHO) in 2019 as one of the ten threats to global health [1]. AMR is indeed responsible each year for more than 700,000 deaths worldwide and 25,000 deaths in Europe [2]. More than 10 million deaths per year worldwide and beyond 100,000 billion dollars economic loss are predicted by 2050 if antibiotic resistance continues to grow [3]. The emergence of AMR and the scarce development of new antibiotics could lead in the near future to a lack of effective antibiotics. Excessive and inappropriate antibiotic use are major drivers of the development of antibiotic resistance worldwide [4–6].

For the last 20 years, antimicrobial stewardship (AMS) has been one of the pillars of the fight against antibiotic resistance, along with infection control. Antimicrobial stewardship programs (ASPs) have been introduced in response to the threat of AMR with the aim to optimize antibiotic use and to improve the quality of infection care [7, 8]. ASPs’ effectiveness has been demonstrated in both hospital and community settings [9, 10], with evidence of decreased antibiotic treatment duration, reduced length of hospital stay and reduced incidence rates of colonization and infection with resistant bacteria [9, 11, 12]. ASPs often consist of various components, such as improved microbiological diagnosis with enhanced collaboration between clinical and microbiological teams, prospective audit and feedback on antibiotic prescribing, prescriber education and training as well as clinical decision support at the point-of-care [8–10]. Despite being widely implemented in hospital settings, ASPs remain rare in primary care settings. However, in Europe, primary care accounts for more than 90% of total antibiotic consumption [4]. Community-based physicians and especially general practitioners (GPs) are therefore the main prescribers of antibiotics. Given the major volume of antibiotic misuse in primary care and the threat of AMR, there is an urgent need to identify and develop new interventions to improve antibiotic use in the community.

The use of antibiotics in primary care involves several health professionals, including community pharmacists. In addition to being medication experts, community pharmacists are often the most accessible and available health care providers to patients. Community pharmacists are often patients’ first point of contact and thus play a key role in patients’ self-management of infections and GP referral. In addition, they are often the last health professional seen by patients before treatment initiation, making them the ideal provider to educate patients about appropriate medication use. Most community pharmacies also benefit from being located close to patients. In France, the French Directorate for Research, Studies, Evaluation and Statistics (DREES) reported that community pharmacies are among the most evenly distributed health services [13]. In addition, the scope of community pharmacy practice in several countries has been expanding in recent years, incorporating vaccine administration [14, 15], point-
was then arranged with pharmacists who consented to participate in the study. Given the ongoing COVID-19 pandemic, all interviews except one sent by mail to pharmacists who expressed interest in participating in the study following the first email. A detailed information sheet and a consent form were subsequently sent by the “Union Régionale des Professionnels de Santé pharmaciens Île-de-France” organization who then disseminated it to their members through email. A detailed information sheet and a consent form were subsequently sent by mail to pharmacists who expressed interest in participating in the study following the first email. A detailed information sheet and a consent form were subsequently sent by mail to pharmacists who expressed interest in participating in the study following the first email. A face-to-face or videoconference interview was then arranged with pharmacists who consented to participate in the study. Given the ongoing COVID-19 pandemic, all interviews except one

However, the implementation of AMS practices is often complex due to contextual barriers resulting in limited adoption of best practices by health care professionals [24]. These barriers may be structural, organisational or cultural, such as lack of financial and human resources or lack of acceptability by providers. These obstacles are even more significant in primary care [24]. Indeed, the implementation of AMS interventions in primary care faces specific challenges, such as infrequent training [25, 26], lack of time [27], uncertain diagnosis [27], lack of systematic follow-up [27, 28] or pressure to prescribe from patients or patients’ family members [27–29]. These challenges are barriers to the successful implementation of interventions and the adoption of improved practices by practitioners. In addition, many interventions found to be effective in public health research fail to achieve significant patient benefit outcomes in real-life practice. Public health interventions researchers recognize the need to assess not only the outcomes of interventions but also their implementation process to determine the extent to which interventions are effective in some specific contexts and can be transposed in other contexts. Theoretical frameworks have therefore been developed to help researchers understand common implementation constructs that can determine the successful implementation of interventions and how they apply in a specific context. The Consolidated Framework for Implementation Research (CFIR) is a comprehensive framework that identifies and specifies constructs from published implementation theories that are recognized to influence implementation positively or negatively [30]. The CFIR is composed of five major domains, including intervention characteristics, outer setting, inner setting, characteristics of individuals and implementation process [31]. The CFIR provides a pragmatic framework for approaching complex, multi-level and multi-stakeholder settings such as primary care settings.

Objectives

The main purpose of this study was to identify specific opportunities for AMS in community pharmacies to target future antibiotic stewardship interventions. We also sought to identify specific barriers and facilitators to community pharmacists’ current and potential role in AMS, in order to identify strategies which could facilitate the implementation of future AMS interventions in pharmacies. Using a theoretical framework to assess the feasibility and acceptability of implementing AMS interventions in the pharmacy setting is an innovative approach to understand this complex care setting at the individual, interpersonal and organizational levels.

Material And Methods

Study design

We conducted a qualitative study using in-depth semi-structured individual interviews. The study is reported in accordance with the Consolidated Criteria for Reporting Qualitative studies (COREQ) checklist [32] (see Additional file 1).

Interview guide

An interview guide was developed after reviewing previous published studies and CFIR theoretical constructs [31]. The interview guide, composed of twenty-three questions, was then reviewed and validated by several AMS specialists and several community pharmacists. In order to test the guide’s relevance and the formulation of its questions, the interview guide was tested in February 2021 during two preliminary individual interviews with community pharmacists recruited through a convenience sampling method. The interview guide is presented in the Additional file 2.

Participant selection

The participant selection was informed by theoretical sampling with inclusion of individuals working as a pharmacist in a community-based pharmacy in France. Individuals not practicing as community pharmacist in France or unable to speak French were excluded as study participants. For the purpose of obtaining a maximum variation sample in terms of sociodemographic status, we combined two recruitment methods. We recruited the majority of the respondents through a professional organization of community pharmacists, the “Union Régionale des Professionnels de Santé pharmaciens Île-de-France”. A snowballing technique and convenience sampling were used to recruit additional participants.

Data collection

An invitation letter describing the overall subject of the study was first sent to the “Union Régionale des Professionnels de Santé pharmaciens Île-de-France” organization who then disseminated it to their members through email. A detailed information sheet and a consent form were subsequently sent by mail to pharmacists who expressed interest in participating in the study following the first email. A face-to-face or videoconference interview was then arranged with pharmacists who consented to participate in the study. Given the ongoing COVID-19 pandemic, all interviews except one
were conducted by videoconference using the Zoom application. All interviews were conducted in French by the first author over a four-month period between February and May 2021 in the Parisian area, France. After informed oral and written consent was obtained from the participants, the interviews were audio recorded using a dictaphone. The socio-demographic data of each participant were collected at the end of each interview. Participant recruitment was continued until data saturation was obtained. No honorarium was provided to study participants.

Data analysis

Upon completion of the interviews, audio recordings were anonymized and transcribed verbatim using the automatic transcription software NVivo Transcription. Data analysis was then conducted by the first author through the framework analysis method [33]. Qualitative data analysis software NVivo 12 was used to carry out analysis. Thematic analysis was carried out in the following steps: familiarisation with the data, generating codes, searching for themes using an inductive approach, reviewing and organizing themes, and analyzing the results adopting a deductive approach with comparison to previous literature and CFIR constructs [31]. A researchers meeting was subsequently held to discuss the main themes identified through analysis and to discuss themes that might represent intervention opportunities. The data analysis process was conducted in parallel with the interviews and in an iterative fashion, which allowed for new themes to be explored by the searchers as the interviews progressed. Participant sampling and data collection were continued until theme saturation was reached. Upon completion of analysis, a workshop was held between the researchers and community pharmacists to discuss the main findings and conclusions from analysis. The open-source software R for Statistical Computing was used to analyze the participants’ sociodemographic data.

Results

Sample characteristics

A total of 16 interviews were conducted. The mean length of the interviews was 43 minutes. The characteristics of the participants are detailed in Table 1. Half of the participants were women and mean age was 49 years old. The majority of the respondents held the position of pharmacy managers and had more than 20 years of community pharmacy experience. However, the characteristics of the community pharmacies where the participants practiced varied. Indeed, of all pharmacy participants, 3 practiced in rural areas while 7 practiced in neighbourhood pharmacies and 6 in city centre pharmacies. Among the study participants, 3 practiced in low-income neighbourhoods.
Table 1
Sociodemographic characteristics of participants

| Sociodemographic characteristics | n = 16 (%) |
|----------------------------------|-----------|
| Community pharmacists            |           |
| Gender                           |           |
| Male                             | 8 (50)    |
| Female                           | 8 (50)    |
| Age (years)                      |           |
| < 30                             | 3 (19)    |
| 30–39                            | 1 (6)     |
| 40–49                            | 3 (19)    |
| 50–59                            | 8 (50)    |
| ≥ 60                             | 1 (6)     |
| Job title                        |           |
| Pharmacist manager               | 12 (75)   |
| Assistant pharmacist             | 4 (25)    |
| Community pharmacy practice experience (years) | |
| < 10                             | 4 (25)    |
| 10–19                            | 3 (19)    |
| 20–29                            | 5 (31)    |
| ≥ 30                             | 4 (25)    |
| Community pharmacy practice      |           |
| Number of pharmacists at the pharmacy (full-time equivalent) | |
| ≤ 2                              | 8 (50)    |
| > 2                              | 8 (50)    |
| Number of pharmacy staff at the pharmacy (full-time equivalent) | |
| ≤ 2                              | 7 (44)    |
| > 2                              | 9 (56)    |
| Pharmacy structure               |           |
| Group                            | 11 (69)   |
| Independant                      | 5 (31)    |
| Current practice location        |           |
| Neighbourhood pharmacy           | 7 (44)    |
| City centre pharmacy             | 6 (37)    |
| Rural pharmacy                   | 3 (19)    |

Thematic analysis

Thematic analysis yielded 6 main themes, which are detailed as follows.

1) Perceptions on AMR and inappropriate antibiotic use

The majority of the respondents reported good knowledge and awareness about AMR, for which they credited the initial training curriculum for pharmacists.

All respondents reported being frequently confronted with inappropriate antibiotic prescribing by GPs and dentists as well as patient antibiotic misuse. Participants’ perceptions towards inappropriate antibiotic use in the community are summarized in Table 2. The majority of participants
cited a lack of knowledge and false beliefs among patients, contributing to prescribing pressure on prescribers and dispensing pressure on pharmacists as well as self-medication with antibiotics and a lack of compliance with antibiotic prescriptions from patients.

| Community pharmacists’ perceptions | n = 16 (%) |
|------------------------------------|------------|
| Inappropriate patient behavior regarding antibiotics | 10 (63) |
| Pressure on pharmacists to dispense antibiotics without prescription | 7 (44) |
| Lack of knowledge regarding AMR and antibiotic use | 7 (44) |
| Pressure on GPs to prescribe antibiotics | 6 (38) |
| Non-adherence to dosage or duration of prescribed antibiotics | 6 (38) |
| Self-medication with antibiotics | 6 (38) |
| Inappropriate antibiotic prescribing practices | 5 (38) |
| Inappropriate prescribing regarding choice of antibiotic | 5 (31) |
| Inappropriate prescribing regarding antibiotic dosage | 3 (19) |
| Over-prescription of antibiotics in situations when not required | 3 (19) |
| Improvement of prescribing practices in recent years | 3 (19) |

“Think it’s a really big pressure on GPs. I think there are times when they wouldn’t prescribe antibiotics or they would delay prescribing and they can’t.” (P8)

“We also have patients demanding antibiotics when it’s not appropriate like when people tell us: “I would like an antibiotic because I have a sore throat”.” (P12)

“Patient compliance is the real issue. If you look at it closely, a lot of patients don’t take antibiotics for the prescribed duration.” (P12)

All study participants believed community pharmacists had an important role to play in tackling AMR. Some pharmacists described having been involved in AMS activities, including per-unit antibiotic dispensing, rapid strep testing, delayed antibiotic prescribing or relying on clinical decision support systems (CDSSs) for checking antibiotic prescriptions compliance with guidelines.

“Absolutely, pharmacists have to be involved.” (P11)

2) Current practices in the management of infections

Many study participants reported patients often first seek advice and treatment from community pharmacists when showing early signs of infection before medical consultation. According to the respondents, the most frequent infectious situations for which patients consult community pharmacists are urinary tract infections, dental infections and upper respiratory tract infections. When asked about how they manage infections, participants reported different courses of action and patient care trajectories depending on the cause of infection (e.g. viral, bacterial), the patient profile (e.g. comorbidities, patient history), the clinical presentation (e.g. severe or atypical presentation) and the time from onset of symptoms. Subsequent management is summarized in Figure 1. For instance, when faced with patients presenting symptoms suggestive of viral infection such as nasopharyngitis, the vast majority of participants described providing self-care advice, combined with over-the-counter (OTC) medication, without systematic referral to a GP.

GP: General practitioner; OTC: Over-the-counter

3) Current antibiotic dispensing practices

Regarding the dispensing process, the majority of participants described usually questioning patients about the physician’s diagnosis as well as their medical history and usual treatment. Most participants also reported systematically assessing clinical safety parameters like allergies or drug interactions with the help of pharmacy management systems. Many participants also stated that they screened prescriptions for prescribing errors and compliance with guidelines. In addition, the majority of respondents viewed dispensation as the appropriate time to raise patient awareness about the importance of medication adherence, especially the duration and dosage of treatment.
"We make sure to write down the dosage and we tell them: “Even if symptoms get better after three days, you have to go through with the treatment (...)” (P13)

They also reported that they usually provide information on the expected adverse effects of treatment. Participants described occasional interactions with prescribers regarding prescribing errors, especially allergies, drug interactions as well as inappropriate antibiotic selection, dosage or duration.

4) Barriers to community pharmacists’ participation in AMS

Several barriers to community pharmacists’ role in current and future AMS activities were cited by the participants, as presented in Table 3. More than half of the participants recognized the lack of access to medical diagnosis and patients’ medical records as a major barrier to pharmacists’ screening of prescriptions for guideline compliance.

Table 3
Barriers, facilitators and potential levers to community pharmacists’ participation in AMS

| Barriers                                                                 | n = 16 (%) |
|-------------------------------------------------------------------------|------------|
| Lack of access to medical diagnosis and records                         | 11 (69)    |
| GPs’ lack of acceptability of pharmacists’ prescription review          | 8 (50)     |
| Lack of time                                                             | 6 (38)     |
| Pharmacists’s lack of specialized knowledge on ID and AMS               | 5 (31)     |
| Pharmacy staff’s lack of skills and qualifications                     | 5 (31)     |
| Difficulties in reaching GPs                                           | 3 (19)     |
| Facilitators                                                            | Levers for future AMS interventions n = 16 (%) |
| Accessibility and availability of pharmacists/First point of contact    | 11 (69)    |
| Trust relationship with patients                                        | 11 (69)    |
| Implementation of CDSSs in pharmacies                                   | ✔ 11 (69) |
| Policies and legal framework for pharmacists’ AMS activities            | ✔ 11 (69) |
| Enhanced interprofessional collaboration with GPs                       | ✔ 9 (56)   |
| Specialized training in ID and AMS/Continuing training                  | ✔ 8 (50)   |
| Experience and expert knowledge about medication                         | 7 (44)     |
| General public’s positive opinion towards pharmacists                   | 5 (31)     |
| Younger GPs’ positive opinion towards GP-pharmacist collaboration       | 5 (31)     |
| No appointment required for consultation in pharmacies                  | 5 (31)     |
| Use of pharmacy management systems for decision support                 | ✔ 5 (31)   |
| Public information and awareness campaigns on AMS                       | ✔ 4 (25)   |
| Long opening hours in pharmacies                                        | 4 (25)     |
| Patient knowledge and cross-disciplinary approach                       | 4 (25)     |
| Financial incentives/Reimbursement models                               | ✔ 3 (19)   |
| Last health professional contact before treatment initiation            | 3 (19)     |
| Availability of Shared Medical Records in pharmacies                    | ✔ 2 (13)   |

AMS: antimicrobial stewardship; CDSSs: Clinical Decision Support Systems; GPs: general practitioners; ID: infectious diseases

"(...) sometimes we lack information about the situation because some patients are not able to tell us the reason why their physician prescribed an antibiotic (...)” (P15)

Complicated interactions with GPs and prescribers’ lack of acceptability to accept questioning or potential changes to prescriptions were another important barrier to the implementation of audits and feedback on the quality and safety of antibiotic prescriptions by pharmacists (n=8/16, 50%).

“I tell you, sometimes when pharmacists call doctors about inappropriate dosage, some doctors will agree to change the prescription but others will tell us to go through with their prescription and supply the inappropriate dosage anyway.” (P6)
Pharmacists’ lack of time (n=6/16, 38%) and lack of expertise on infections (n=5/16, 31%) were also mentioned by some participants as well as pharmacy staff’s lack of qualifications to perform AMS activities (n=5/16, 31%).

5) Facilitators to community pharmacists’ participation in AMS

Multiple enablers intrinsic to the pharmacy profession as well as potential levers for future interventions that may facilitate their role in patient management and the appropriate use of antibiotics were also described by the participants. They are listed in Table 3. Most participants recognized as intrinsic assets the fact that community pharmacists are well-positioned (n=11/16, 60%), knowledgeable (n=7/16, 44%) providers as well as well-regarded health professionals by service users (n=5/16, 31%).

According to respondents, community pharmacists’ trust relationship with patients (n=11/16, 69%) and their direct involvement in antibiotic supply for the community give them leverage to raise patient awareness about AMR and antibiotic use.

“Our interactions with patients are a bit more informal, which makes it easier to build rapport and raise awareness.” (P15)

“People talk to pharmacists easily. I think they trust us and they listen to us. Besides, we usually take the time for people who come in.” (P4)

Among levers that could be implemented to facilitate pharmacists’ role in AMS interventions, over half the participants named the development of collaborative relationships with GPs. Nearly 70% of respondents also stressed the importance of implementing clear policies and protocols to support pharmacists’ involvement in AMS activities. In addition, half the respondents emphasized the value of continuing education for community pharmacists to update their knowledge of prescribing guidelines and infection management.

“But it would need for pharmacists to be well trained on these topics. For many of my colleagues, I think trainings go back a long way so it would be necessary for them to do training. But I think a lot of pharmacists would agree to participate in trainings.” (P7)

Another facilitator mentioned by nearly a third of the participants was the change in mentality among younger generations of GPs. According to several study participants, younger GPs are more favorable toward pharmacists’ uptake of non-traditional roles and generally more inclined to interprofessional cooperation.

Furthermore, as part of integrating a methodological framework in this study, barriers and facilitators identified through analysis were systematically compared and linked to the corresponding CFIR constructs as well as to the levels to which these implementation factors refer. These findings are presented in Table 4.
### Table 4
Synthesis of barriers and facilitators to community pharmacists’ participation in AMR and corresponding CFIR constructs

| Levels                      | Barriers                                                                 | Facilitators                                                                 | Constructs CFIR                  |
|-----------------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------|----------------------------------|
| Community pharmacists       | Pharmacy staff’s lack of skills and qualifications                       | Continuing training/Specialized training in ID and AMS                         | Learning Climate                 |
|                             | Pharmacists’s lack of specialized knowledge on ID and AMS                 |                                                                              |                                  |
| Relationship with users     | Accessibility and availability of pharmacists/First point of contact     | Last health professional contact before treatment initiation                   | Patient Needs and Resources       |
|                             |                                                                         | Trust relationship with patients                                             | Patient Needs and Resources       |
|                             |                                                                         | Accessibility and availability of pharmacies/First point of contact           | Patient Needs and Resources       |
|                             |                                                                         | Last health professional contact before treatment initiation                 | Patient Needs and Resources       |
|                             |                                                                         | Trust relationship with patients                                             | Patient Needs and Resources       |
| Relationship with GPs       | GPs’ lack of acceptability of pharmacists’ prescription review            | Younger GPs’ positive opinion towards GP-pharmacist collaboration             | Implementation Climate            |
|                             |                                                                         | Difficulties in reaching GPs                                                 | Networks and Communications       |
| Pharmacy policy and health system organization | Lack of access to medical diagnosis and records | Availability of Shared Medical Records in pharmacies | Available Resources |
|                             | Lack of time                                                             |                                                                              | Available Resources               |
|                             |                                                                         | Financial incentives/Reimbursement models                                     | Organizational Incentives and Rewards |
|                             |                                                                         | Policies and legal framework for pharmacists’ AMS activities                 | External Policies and Incentives  |
|                             |                                                                         | Implementation of CDSSs in pharmacies                                        | Access to Knowledge and Information |
|                             |                                                                         | Use of pharmacy management systems for decision support                     | Access to Knowledge and Information |

AMS: antimicrobial stewardship; CFIR: Consolidated Framework for Implementation Research; CDSSs: Clinical Decision Support Systems; GPs: general practitioners; ID: infectious diseases

### 6) Potential AMS interventions in community pharmacies

Several opportunities for AMS interventions in community pharmacies were mentioned by the study participants, one of which is increasing patient education about the rational use of antibiotics (n=15/16, 96%) during infection consultation and antibiotic dispensing at the pharmacy. For example, educational and training materials, such as leaflets, could support and further enhance current education practices. Such improved patient education may reduce patients’ expectations to receive antibiotics for common viral infections and therefore decrease the pressure on GPs to prescribe antibiotics. It may as well improve patients’ adherence to antibiotic therapies.

“(…) that’s where pharmacists’ role comes into play. Because we know which patients are always demanding for antibiotics, we can try to educate them.” (P3)
Another intervention discussed during the interviews was for pharmacists to conduct audits of antibiotic prescribing with feedback to prescribers, although some participants expressed concerns about the acceptability of GPs and the feasibility of this kind of interventions without pharmacists’ access to medical diagnosis. Nevertheless, the majority of respondents believed the implementation of CDSSs in pharmacies to display clinical practice guidelines could support pharmacists’ prescription screening and assist potential audits of antibiotic prescribing in pharmacies. Some participants stressed the importance of integrating such tools with pharmacy management software.

“If pharmacists check every prescription and they have to go and find the official guidelines themselves, it’s too difficult. But if we had a tool that could help us check compliance with guidelines after supplying information then there would be a double check, which is always better.” (P2)

“But then, I think that with electronic tools, there are simple things that can be set up. With management software for example, there are ways of setting up pop-ups with decision trees or queries.” (P4)

All participants were confident in the ability of pharmacists to prescribe and dispense antibiotics without medical consultation for the treatment of uncomplicated infections such as uncomplicated cystitis or streptococcal pharyngitis. Moreover, many participants pointed out the patient benefits that such interventions could have.

“I think given the current difficult access to care for some patients, it could be beneficial in some situations. But it should not be fully open. We need decision trees. We need a clear framework. I think in many cases it would allow for quick treatment of infection.” (P4)

In addition, some participants (n=4/16, 25%) highlighted the need for increased point-of-care testing in community pharmacies, namely urine dipstick and rapid strep testing, to optimize patient triage and prioritize patient referral to GPs for infections requiring antibiotic therapy. Some participants (n=4/16, 25%) also stressed the benefits of having patients returning leftover antibiotic tablets to reduce self-medication.

**Discussion**

**Main findings**

This qualitative study, guided by the CFIR, explores French community pharmacists’ perceptions about the implementation of AMS interventions in community pharmacy practice. The findings suggest that French community pharmacists are well-aware of AMR and antibiotic misuse in the community. Moreover, participants expressed strong interest in playing a bigger role in the management of common infections and in participating in AMS by incorporating AMS practices targeting prescribers and users into their practice. However, several barriers to implementing such activities into community pharmacy practice were cited during the interviews, such as lack of access to medical diagnosis, difficult interactions with GPs, lack of time and lack of specialized knowledge regarding the management of infections. These barriers go beyond the individual characteristics of pharmacists and relate to the overall organization of community pharmacies and primary care. It is worth mentioning that the interactions between community pharmacists and GPs were described as a barrier as well as a facilitator when an informal collaborative framework existed between the health care professionals. Similarly, some of the facilitators mentioned, such as continuing education and specialized training, clinical decision support and the implementation of Shared Medical Records (SMRs) in community pharmacies, could be promising strategies to remove the above-mentioned barriers.

The barriers and facilitators identified during the interviews were systematically linked the theoretical constructs listed in the CFIR. Participants suggested potential facilitators for interventions that confirmed validated recommendations such as the Expert Recommendations for Implementing Change (ERIC) [34, 35]. For instance, as far as interpersonal relations are concerned, ERIC strategies recommend creating an alliance and organizing local discussions [35]. As for overcoming organizational barriers, ERIC strategies suggest involving administrative structures and creating incentives [35].

Among the opportunities for AMS suggested by the participants, one can note the expansion of community pharmacists’ prescribing rights. The positive effects of expanding prescribing for community pharmacists were especially expressed by the participants that worked in rural pharmacies. Furthermore, these pharmacists also expressed that they often felt compelled to refer patients with signs of bacterial infections to hospital emergency departments or to dispense antibiotics without prescription, given the lack of GPs in rural areas. A legislated right for pharmacists to supply certain antibiotics without medical consultation in specific conditions like non-complicated UTIs or bacterial pharyngitis could benefit to populations lacking access to primary care services. Given the evenly distribution and the extended hours of community pharmacies, a prescribing role for pharmacists could allow for overall better access to infection care outside opening hours of general practices. Moreover, it could also help to reduce delays in infection care by simplifying the care pathway and reduce GPs’ workload.

The impact of the COVID-19 health crisis on the community pharmacist profession can also be discussed. Indeed, community pharmacists have played a major role in the frontline primary care response to the pandemic by educating the general public about SARS-CoV2 infection and COVID-19 vaccines, performing rapid antigen testing [36] and administering COVID-19 vaccines in pharmacies [37]. The COVID-19 pandemic has highlighted the capacity of community pharmacists to uptake non-traditional roles and to provide key public health care services. One could therefore hypothesize that the recent health crisis has enhanced the position of pharmacists in the primary health care system and the public opinion, paving the way for increased role in AMS.
Comparison with existing literature

The barriers and facilitators that we identified in this study are similar to those found in two qualitative studies conducted in the United Kingdom [21, 22]. Those two studies also considered community pharmacists’ inability to conduct clinical examinations at the pharmacy, the lack of human resources and language barriers between pharmacists and patients as potential barriers to community pharmacists’ participation in AMS. Another obstacle to the implementation of AMS in pharmacies, identified by Jones et al. [21], is the lack of understanding of the concept of antimicrobial resistance by patients. In one systematic review of pharmacists’ knowledge, perceptions and practices regarding antimicrobial stewardship, Saha et al. found that pharmacists’ opinion towards AMS interventions were positive in most studies [23]. However, two studies in that review pinpointed that this opinion varied according to pharmacists’ qualifications and professional experience. More educated and experienced pharmacists were more likely to be favorable to AMS interventions in the pharmacy. In addition, that review found that only 30% of pharmacists routinely checked antibiotic prescriptions for guideline compliance. In addition, the authors of that review and those of one of the qualitative studies [22] considered financial incentives and remuneration for AMS activities as important levers for the successful implementation of AMS interventions in community pharmacies.

Strengths and limitations

This study has several strengths, one of which is the variety of the participants’ sociodemographic profile. This variety was likely obtained thanks to our combination of two participant recruitment methods. We are confident that this profile diversity helped capture the diversity of French community pharmacists’ perspectives and practices. In addition, our collaboration with a professional organization of pharmacists allowed for triangulation of the results during a workshop between the researchers and community pharmacists from the organization. Another strength of this study is the use of a validated methodological framework for the development of the interview guide and thematic analysis. Indeed, the integration of an implementation framework into this research allowed for us to identify interventions that are specifically tailored for the pharmacy setting. Additionally, it helped determine implementation strategies to support the implementation of such interventions thanks to existing expert recommendations [34].

Several limitations can be discussed, such as the existence of a recruitment bias regarding the participant selection. Indeed, one can assume that pharmacists that were willing to participate in this study viewed AMR as an important matter and were prompt on being involved in improvement opportunities. Moreover, this study focused on the perceptions and attitudes of community pharmacists. These perceptions may not be representative of all primary health care providers and stakeholders. We believe the perspectives of other stakeholders like GPs, nurse practitioners and service users should also be explored to properly assess the feasibility and acceptability of AMS interventions in primary care. In addition, this study exclusively focused on the French primary care setting and these results therefore may not be directly generalizable to different health care systems or settings.

Conclusions

This study suggests that community pharmacists’ skills and position in the community are underutilized while the current scope of community pharmacy practice has room for more interventions to improve infection management and the rational use of antibiotics. Community pharmacists’ pharmaceutical expertise as well as their accessibility and close relationship with patients could promote a better utilization of antibiotics by patients and prescribers. Potential facilitators for the effective and sustainable implementation of AMS interventions in community pharmacies are increased GP-pharmacist collaboration, specialized training and Shared Medical Records. Multiple AMS components could be routinely practiced by community pharmacists such as increased patient education through educational materials, increased point-of-care testing and delayed prescribing. Multi-faceted AMS interventions, tailored to the community pharmacy setting and based on interprofessional cooperation, must be implemented and evaluated.

Abbreviations

AMR
Antimicrobial resistance
AMS
Antimicrobial stewardship
ASP
Antimicrobial stewardship program
CDSS
Clinical Decision Support System
CFIR
Consolidated Framework for Implementation Research
ERIC
Expert Recommendations for Implementing Change
Declarations

Ethics approval and consent to participate

This study was approved by the Institutional Review Board (IRB00011642) of the French Infectious Diseases Society (CER-MIT n°2021-0301). Informed consent was obtained from all participants.

Consent for publication

Not applicable

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This work did not receive any grant from funding agencies in the public, commercial, or not-for-profit sectors.

Authors’ contributions

C.D. (Conceptualization, Methodology, Investigation, Data Curation, Formal Analysis, Writing—Original Draft Preparation); A.C. (Methodology, Resources, Writing—Review & Editing); E.D. (Methodology, Resources, Writing—Review & Editing); F.P. (Methodology, Resources, Writing—Review & Editing); R.A. (Conceptualization, Methodology, Writing—Review & Editing); F.-X.L. (Conceptualization, Methodology, Writing—Review & Editing, Project Administration, Supervision); N.P.-S. (Conceptualization, Methodology, Data Curation, Formal Analysis, Validation, Writing—Original Draft Preparation, Writing—Review & Editing, Project Administration, Supervision).

The authors would like to thank the elected representatives of the URPS pharmaciens Ile de France organization for their support of the study.

References

1. World Health Organization (WHO). Ten threats to global health in 2019. 2019 [cited 2021 Mar 17]; Available from: https://www.who.int/emergencies/ten-threats-to-global-health-in-2019
2. ECDC/EMEA. Joint Technical Report: The bacterial challenge: time to react. 2009 [cited 2021 Mar 17]; Available from: https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf
3. O’Neill J. Tackling Drug-Resistant Infections Globally: final report and recommendations. 2016 [cited 2021 Jun 3]; Available from: https://amr-review.org/
4. Goossens H, Ferech M, Vanderstichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. The Lancet. 2005;365:579–87.
5. Costelloe C, Metcalf C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ. British Medical Journal Publishing Group; 2010;340:c2096.
6. Holmes AH, Moore LSR, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387:176–87.
7. Tamma PD, Cosgrove SE. Antimicrobial Stewardship. Infectious Disease Clinics of North America. 2011;25:245–60.
8. Dyar OJ, Huttner B, Schouten J, Pulcini C, ESGAP (ESCMID Study Group for Antimicrobial stewardship). What is antimicrobial stewardship? Clin Microbiol Infect. 2017;23:793–8.

9. Davey P, Marwick CA, Scott CL, Charani E, McNeil K, Brown E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Effective Practice and Organisation of Care Group, editor. Cochrane Database of Systematic Reviews [Internet]. 2017 [cited 2020 Mar 1]; Available from: http://doi.wiley.com/10.1002/14651858.CD003543.pub4

10. Dyar OJ, Beović B, Vlahović-Palčevski V, Verheji T, Pulcini C. How can we improve antibiotic prescribing in primary care? Expert Review of Anti-infective Therapy. Taylor & Francis; 2016;14:403–13.

11. Seppälä H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K, et al. The Effect of Changes in the Consumption of Macrolide Antibiotics on Erythromycin Resistance in Group A Streptococci in Finland. N Engl J Med. 1997;337:441–6.

12. Guillermot D, Varon E, Bernede C, Weber P, Henriet L, Simon S, et al. Reduction of Antibiotic Use in the Community Reduces the Rate of Colonization with Penicillin G–Nonsusceptible Streptococcus pneumoniae. Clinical Infectious Diseases. 2005;41:930–8.

13. Ordre national des pharmaciens. Démographie des pharmaciens - Panorama au 1er janvier 2020. 2020 Jan [cited 2021 Jun 3]; Available from: http://www.ordre.pharmaciens.fr/content/download/506716/2312914/version/1/file/DEMOGRAPHIE-2020.pdf

14. Hogue MD, Grabenstein JD, Foster SL, Rothholz MC. Pharmacist involvement with immunizations: a decade of professional advancement. J Am Pharm Assoc (2003). 2006;46:168–79; quiz 179–82.

15. Czech M, Balcerzak M, Antczak A, Byliniak M, Piotrowska-Rutkowska E, Drozd M, et al. Flu Vaccinations in Pharmacies-A Review of Pharmacists Fighting Pandemics and Infectious Diseases. Int J Environ Res Public Health. 2020;17.

16. Essack S, Bell J, Burgoyne D, Tongrod W, Duerden M, Sessa A, et al. Point-of-Care Testing for Pharyngitis in the Pharmacy. Antibiotics (Basel). 2020;9:E743.

17. Wu JH-C, Khalid F, Langford BJ, Beahm NP, McIntyre M, Schwartz KL, et al. Community pharmacist prescribing of antimicrobials: A systematic review from an antimicrobial stewardship perspective. Can Pharm J (Ott). 2021;154:179–92.

18. Booth JL, Mullen AB, Thomson DA, Johnstone C, Galbraith SJ, Bryson SM, et al. Antibiotic treatment of urinary tract infection by community pharmacists: a cross-sectional study. Br J Gen Pract. 2013;63:e244–9.

19. Saha SK, Kong DCM, Thursky K, Mazza D. Antimicrobial stewardship by Australian community pharmacists: Uptake, collaboration, challenges, and needs. J Am Pharm Assoc (2003). 2021;61:158-168.e7.

20. Bianco A, Licata F, Trovato A, Napolitano F, Pavia M. Antibiotic-Dispensing Practice in Community Pharmacies: Results of a Cross-Sectional Study in Italy. Antimicrob Agents Chemother. 2021;65:e02729-20.

21. Jones LF, Owens R, Sallis A, Ashiru-Oredope D, Thornley T, Francis NA, et al. Qualitative study using interviews and focus groups to explore the current and potential for antimicrobial stewardship in community pharmacy informed by the Theoretical Domains Framework. BMJ Open. 2018;8:e025101.

22. Peiffer-Smadja N, Allison R, Jones LF, Holmes A, Patel R, Lecky DM, et al. Preventing and Managing Urinary Tract Infections: Enhancing the Role of Community Pharmacists—A Mixed Methods Study. Antibiotics. 2020;9:583.

23. Saha SK, Barton C, Promite S, Mazza D. Knowledge, Perceptions and Practices of Community Pharmacists Towards Antimicrobial Stewardship: A Systematic Scoping Review. Antibiotics. 2019;8:263.

24. Arnold SR, Straus SE. Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database Syst Rev. 2005;CD003539.

25. Steinke DT. Practice factors that influence antibiotic prescribing in general practice in Tayside. Journal of Antimicrobial Chemotherapy. 2000;46:509–12.

26. Mainous AG, Hueston WJ, Love MM. Antibiotics for colds in children: who are the high prescribers? Arch Pediatr Adolesc Med. 1998;152:349–57.

27. Dempsey PP, Businger AC, Whaley LE, Gagne JJ, Linder JA. Primary care clinicians’ perceptions about antibiotic prescribing for acute bronchitis: a qualitative study. BMC Fam Pract. 2014;15:194.

28. Watson RL, Dowell SF, Jayaraman M, Keyserling H, Kolczak M, Schwartz B. Antimicrobial use for pediatric upper respiratory infections: reported practice, actual practice, and parent beliefs. Pediatrics. 1999;104:1251–7.

29. Butler CC, Rollnick S, Pill R, Maggs-Rapport F, Stott N. Understanding the culture of prescribing: qualitative study of general practitioners’ and practices: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50.

30. Damshcroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research ndings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2005;CD003539.

31. CFIR Research Team. Constructs – The Consolidated Framework for Implementation Research [Internet]. [cited 2021 Jun 8]. Available from: https://cfiguide.org/constructs/

32. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19:349–57.
33. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Medical Research Methodology. 2013;13:117.

34. Powell BJ, Waltz TJ, Chinman MJ, Damschroder LJ, Smith JL, Matthieu MM, et al. A refined compilation of implementation strategies: results from the Expert Recommendations for Implementing Change (ERIC) project. Implementation Science. 2015;10:21.

35. Waltz TJ, Powell BJ, Fernández ME, Abadie B, Damschroder LJ. Choosing implementation strategies to address contextual barriers: diversity in recommendations and future directions. Implementation Science. 2019;14:42.

36. Haute Autorité de Santé. Avis n° 2020.0050/AC/SEAP du 24 septembre 2020 du collège de la Haute Autorité de santé relatif à l’inscription sur la liste des actes et prestations mentionnée à l’article L. 162-1-7 du code de la sécurité sociale, de la détection antigénique du virus SARS-CoV-2 sur prélèvement nasopharyngé [Internet]. 2020 [cited 2021 Jun 4]. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2020-09/avis_n_2020.0050acseap_du_24_septembre_2020_du_college_de_la_haute_autorite_de_sante_relatif_a_linscription_sur_la_liste_des.pdf

37. Haute Autorité de Santé. Avis n° 2021.0023/AC/SEESP du 25 mars 2021 du collège de la Haute Autorité de santé relatif à l’élargissement des compétences vaccinales dans le cadre de la campagne de vaccination de masse contre le SARS-COV-2 [Internet]. 2021 [cited 2021 Jun 4]. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2021-03/avis_n2021.0023_ac_seesp_du_25_mars_2021_du_college_de_la_has_relatif_a_lelargissement_des_competences_vaccinales_dans_le_ca.pdf

**Figures**

![Diagram showing patient flow in community pharmacists' initial approach of common infections.](image-url)

**Figure 1**

Community pharmacists’ initial approach of common infections

**GP**: General practitioner; **OTC**: Over-the-counter

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1.pdf
- Additionalfile2.docx